Comment on: "Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs"
- PMID: 32623593
- PMCID: PMC7347511
- DOI: 10.1007/s40265-020-01353-5
Comment on: "Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs"
Conflict of interest statement
M. Eerdekens and M. Stupar are employees of Grünenthal GmbH, and L. Marcondes is employee of GRT US Holding.
Comment in
-
Authors' Reply to Eerdekens et al. "Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs".Drugs. 2020 Jul;80(11):1141-1143. doi: 10.1007/s40265-020-01351-7. Drugs. 2020. PMID: 32623592 No abstract available.
Comment on
-
Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs.Drugs. 2020 Mar;80(4):363-384. doi: 10.1007/s40265-020-01259-2. Drugs. 2020. PMID: 32040849 Review.
References
-
- Summary of Product Characteristics, Qutenza. https://www.ema.europa.eu/en/documents/product-information/qutenza-epar-.... Accessed Mar 2020.
-
- Schlereth T. et al., Diagnosis and not interventional therapy neuropathic Pain, S2k guideline, 2019, in: German Society for Neurology (ed.), Guidelines for diagnostics and therapy in the Neurology. https://www.dgn.org/images/red_leitlinien/LL_2019/PDFs_Download/030114_L.... Accessed Mar 2020. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
